Lost Money on Myriad Genetics, Inc. (MYGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. (MYGN) for potential federal securities law violations. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test from January 2025.
November 08, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities law violations after UnitedHealth announced it will stop covering GeneSight, a key product, from January 2025.
The investigation by Levi & Korsinsky into Myriad Genetics for potential securities law violations is significant, especially following UnitedHealth's decision to cease coverage of GeneSight. This could negatively impact Myriad's revenue and investor confidence, likely leading to a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100